CAS No. 2370013-49-1
Batch:
Purity:99.76
Chemical Structure
Check the
(S)-Sunvozertinib ((S)-DZD9008)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
| IUPAC Name | N-[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide | |
|---|---|---|
| CAS Number | 2370013-49-1 | |
| Molecular Formula |
C29H35ClFN7O3 |
|
| Molecular Weight (MW) | 584.08 | |
| SMILES | COC1=C(NC2=NC=CC(=N2)NC3=CC(=C(F)C=C3C(C)(C)O)Cl)C=C(NC(=O)C=C)C(=C1)N4CCC(C4)N(C)C | |
| InChIKey | BTMKEDDEMKKSEF-KRWDZBQOSA-N |
(S)-Sunvozertinib ((S)-DZD9008) is an oral, potent, irreversible, wild-type-selective inhibitor of epidermal growth factor receptor (EGFR) targeting mutant EGFR and HER2 exon 20 insertion mutations. In preclinical models, sunvozertinib selectively suppresses EGFR autophosphorylation and downstream signaling through the AKT/mTOR and MAPK/ERK pathways. This targeted inhibition reduces cellular proliferation and promotes apoptosis in non-small cell lung cancer models harboring exon 20 insertions while sparing wild-type EGFR. [1]
|
Concentration
Volume
Mass
|
|---|
Batch:
All in vitro solubility values are batch-tested experimental data (non-literature values).
| Solvent | Solubility & Note |
|---|---|
| DMSO |
100 mg/mL
(171.2 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO. The recommended stock concentration is 10 mM in DMSO.) |
| Ethanol | 25 mg/mL |
| Water | Insoluble |
| DMSO |
100 mg/mL
(171.2 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO. The recommended stock concentration is 10 mM in DMSO.) |
| Ethanol | 25 mg/mL |
| Water | Insoluble |
Q: Why does a DMSO stock precipitate in media/saline?
A: It is caused by unheated aqueous media (supersaturation), local solvent shock, or incorrect mixing sequence.
How to fix it?
- Preheat media/saline to 37°C.
- Mix rapidly (pipette/vortex) upon addition.
- For complex mixes, always add the aqueous phase last.
- Re-dissolve minor precipitates with a 37°C water bath and sonication (≤30 min).
- (S)-Sunvozertinib ((S)-DZD9008) Clinical Trials
- (S)-Sunvozertinib ((S)-DZD9008) Solubility in DMSO
- (S)-Sunvozertinib ((S)-DZD9008) Stock Solution
- (S)-Sunvozertinib ((S)-DZD9008) Storage
- (S)-Sunvozertinib ((S)-DZD9008) Stability
- (S)-Sunvozertinib ((S)-DZD9008) Molecular Weight
- (S)-Sunvozertinib ((S)-DZD9008) SMILES
- (S)-Sunvozertinib ((S)-DZD9008) Chemical Structure (2D and 3D)
- (S)-Sunvozertinib ((S)-DZD9008) SDS|MSDS
Note: Technical data last updated: Sep 1, 2026.